NASDAQ: BLACBellevue Life Sciences Acquisition Corp Stock
$10.70+0.00 (+0%)
Updated Apr 22, 2024
BLAC Price
$10.70
Fair Value Price
N/A
Market Cap
$60.17M
52 Week Low
$10.11
52 Week High
$11.16
P/E
214x
P/B
-15.4x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$403.78k
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.05
Operating Cash Flow
-$819k
Beta
0.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BLAC Overview
Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire companies in the healthcare industry. Bellevue Life Sciences Acquisition Corp. was founded in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.
Zen Score
–
Industry Average (8)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BLAC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLAC is poor value based on its earnings relative to its share price (214x), compared to the US market average (41.92x)
P/E vs Market Valuation
BLAC is poor value based on its earnings relative to its share price (214x), compared to the US Shell Companies industry average (35.77x)
P/E vs Industry Valuation
BLAC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more BLAC due diligence checks available for Premium users.
Be the first to know about important BLAC news, forecast changes, insider trades & much more!
BLAC News
Valuation
BLAC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
214x
Industry
35.77x
Market
41.92x
BLAC is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BLAC is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
BLAC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-15.4x
Industry
-14.4x
BLAC's financial health
Profit margin
Revenue
$0.0
Net Income
-$86.2k
Profit Margin
0%
BLAC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$36.6M
Liabilities
$4.1M
Debt to equity
-1.05
BLAC's short-term liabilities ($2.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLAC's long-term liabilities ($2.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLAC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BLAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$279.5k
Investing
$36.4M
Financing
-$36.1M
BLAC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BLAC vs Shell Company Stocks
Bellevue Life Sciences Acquisition Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.